553 related articles for article (PubMed ID: 19481417)
1. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.
Braden MN; Johns MM; Klein AM; Delgaudio JM; Gilman M; Hapner ER
J Voice; 2010 Mar; 24(2):242-9. PubMed ID: 19481417
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
3. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
Meyer TK; Hu A; Hillel AD
Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
[TBL] [Abstract][Full Text] [Related]
4. Reliability of clinician-based (GRBAS and CAPE-V) and patient-based (V-RQOL and IPVI) documentation of voice disorders.
Karnell MP; Melton SD; Childes JM; Coleman TC; Dailey SA; Hoffman HT
J Voice; 2007 Sep; 21(5):576-90. PubMed ID: 16822648
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Hogikyan ND; Wodchis WP; Spak C; Kileny PR
J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.
Rubin AD; Wodchis WP; Spak C; Kileny PR; Hogikyan ND
Arch Otolaryngol Head Neck Surg; 2004 Apr; 130(4):415-20. PubMed ID: 15096423
[TBL] [Abstract][Full Text] [Related]
7. Perceptual structure of adductor spasmodic dysphonia and its acoustic correlates.
Cannito MP; Doiuchi M; Murry T; Woodson GE
J Voice; 2012 Nov; 26(6):818.e5-13. PubMed ID: 23177751
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal variations of laryngeal overpressure and voice-related quality of life in spasmodic dysphonia.
Yeung JC; Fung K; Davis E; Rai SK; Day AM; Dzioba A; Bornbaum C; Doyle PC
Laryngoscope; 2015 Mar; 125(3):661-6. PubMed ID: 25290557
[TBL] [Abstract][Full Text] [Related]
9. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
[TBL] [Abstract][Full Text] [Related]
10. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
11. Combined modality treatment of adductor spasmodic dysphonia.
Silverman EP; Garvan C; Shrivastav R; Sapienza CM
J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
[TBL] [Abstract][Full Text] [Related]
12. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
[TBL] [Abstract][Full Text] [Related]
13. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
14. The relationship between ratings of voice quality and quality of life measures.
Murry T; Medrado R; Hogikyan ND; Aviv JE
J Voice; 2004 Jun; 18(2):183-92. PubMed ID: 15193651
[TBL] [Abstract][Full Text] [Related]
15. Voice handicap index results for older patients with adductor spasmodic dysphonia.
Wingate JM; Ruddy BH; Lundy DS; Lehman J; Casiano R; Collins SP; Woodson GE; Sapienza C
J Voice; 2005 Mar; 19(1):124-31. PubMed ID: 15766857
[TBL] [Abstract][Full Text] [Related]
16. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
17. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
Adams SG; Hunt EJ; Charles DA; Lang AE
J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life and Voice Changes After a Single Injection in Patients With ADSD Over Time.
Faham M; Torabinezhad F; Murry T; Dabirmoghaddam P; Abolghasemi J; Kamali M; Asgari M
J Voice; 2019 Sep; 33(5):721-727. PubMed ID: 29884509
[TBL] [Abstract][Full Text] [Related]
19. Perceptual analyses of spasmodic dysphonia before and after treatment.
Cannito MP; Woodson GE; Murry T; Bender B
Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1393-9. PubMed ID: 15611398
[TBL] [Abstract][Full Text] [Related]
20. Clinical practice guideline: hoarseness (dysphonia).
Schwartz SR; Cohen SM; Dailey SH; Rosenfeld RM; Deutsch ES; Gillespie MB; Granieri E; Hapner ER; Kimball CE; Krouse HJ; McMurray JS; Medina S; O'Brien K; Ouellette DR; Messinger-Rapport BJ; Stachler RJ; Strode S; Thompson DM; Stemple JC; Willging JP; Cowley T; McCoy S; Bernad PG; Patel MM
Otolaryngol Head Neck Surg; 2009 Sep; 141(3 Suppl 2):S1-S31. PubMed ID: 19729111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
